PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16212515

Using visual displays as a tool to demonstrate disease management program effectiveness.

Ariel Linden·Nancy Roberts
View original source ↗Export metadata ↓

Abstract

With the rapid introduction of new medical and information technologies, there are much more data available today than ever before. Translating data into useful information for a wide variety of audiences is a challenge for health care in general and disease management programs in particular. This paper addresses these issues by introducing several visual displays that illustrate important data elements in an unencumbered fashion. Examples are provided using the various stages of a hypothetical congestive heart failure (CHF) disease management program (ie, patient identification, program enrollment, intervention process, and outcomes evaluation).

Explore related subjects

Coronary DiseaseData DisplayDiabetes MellitusDisease ManagementHeart FailureHumansModels, StatisticalOutcome Assessment, Health CareProgram EvaluationJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ariel Linden, Nancy Roberts. 2005. Using visual displays as a tool to demonstrate disease management program effectiveness.. https://doi.org/10.1089/dis.2005.8.301

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗
PubMed2007

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗